The National Health Surveillance Agency (Anvisa) has initiated a regulatory process aimed at establishing specific rules on logistics and delivery of medicines on e-commerce platforms and digital channels. The measure represents an important step in adapting Brazil's sanitary regulations to new models of pharmaceutical product commercialization.
The process seeks to create clear guidelines to ensure the safety, quality and traceability of medicines sold through digital means. With the exponential growth of pharmaceutical e-commerce in recent years, Anvisa recognizes the need to regulate specific aspects of the distribution chain in this segment.
Among the points to be addressed by the regulation are requirements for adequate storage, temperature control, appropriate packaging, verification of product authenticity and procedures to ensure that only legitimate medicines reach consumers. The goal is to minimize risks of counterfeiting and ensure that products maintain their physical and chemical characteristics during transport.
The opening of this regulatory process also aims to establish clear responsibilities among e-commerce platforms, distributors, carriers and pharmacies in the delivery chain. This includes definitions about who is responsible for product integrity at each stage of logistics.
Anvisa invites all interested parties to participate in the public consultation that will be opened during this regulatory process. The participation of pharmacies, distributors, digital platforms, professional associations and other stakeholders is fundamental to the development of efficient and viable regulations.
This initiative reflects Anvisa's commitment to monitoring the evolution of the pharmaceutical market while maintaining the highest sanitary safety standards. The regulation of pharmaceutical e-commerce is essential to protect public health and ensure that consumers have access to quality products through digital channels.
